NCT04261439View on ClinicalTrials.gov

A Phase I/Ib Study of NIZ985 Alone and in Combination With Spartalizumab

PHASE1TerminatedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

February 27, 2020

Primary Completion Date

December 27, 2023

Study Completion Date

December 27, 2023

Conditions
In Escalation: All Patients With Solid Tumors and LymphomaIn Expansion: Melanoma, Non-small Cell Lung Cancer
Interventions
DRUG

NIZ985

NIZ985 injection

DRUG

Spartalizumab

Spartalizumab infusion

DRUG

Tislelizumab

Tislelizumab infusion

Trial Locations (9)

3000

Novartis Investigative Site, Leuven

10048

Novartis Investigative Site, Taipei

28009

Novartis Investigative Site, Madrid

45147

Novartis Investigative Site, Essen

80131

Novartis Investigative Site, Napoli

91010

City of Hope National Medical, Duarte

92093

Moores UCSD Cancer Center, La Jolla

104 0045

Novartis Investigative Site, Chuo Ku

08035

Novartis Investigative Site, Barcelona

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY